Thanks for your post sultanvinegar. You are correct, I should've...

Thanks for your post sultanvinegar.

You are correct, I should've cited primary sources, ie. the WARF application linked below or from the USPTO - as you have done.

https://www.google.com.au/url?sa=t&...E9h4JLG8dWDlhXQIZTzv-g&bvm=bv.108194040,d.dGY

However, I can't find any detail on it being licensed to Cynata or an Appendix B3. Could you please highlight where in the patent it references Cynata?

"their [FDA] mandate is to ensure safe and effective medicines".

I refer to the Cynata patent which expressly covers lentiviral delivery of transgenes to make iPSCs. Compare that to our current understanding: "Current methods for generating iPS cells employ retroviral vectors such as those derived from lentivirus. These vectors stably integrate into, and permanently change, a target cell's DNA at virtually any chromosomal locus. " - Thomson and Yu, in reference to http://www.ncbi.nlm.nih.gov/pubmed/17554338; and Retroviral Integrations in Gene Therapy Trials by Biasco et al. (2012) http://www.nature.com/mt/journal/v20/n4/full/mt2011289a.html.

The Cymerus technology is no longer considered safe, because the source iPSCs were made through outdated methods.